Alnylam Pharmaceuticals (ALNY) Equity Income (2009 - 2012)

Alnylam Pharmaceuticals has reported Equity Income for 4 years, with the latest figure at -$881000.0 in Q4 2012.

• For the quarter ending Q4 2012, Equity Income rose 7.65% year-over-year to -$881000.0; the trailing twelve-month figure through Dec 2012 stood at -$4.5 million (down 29.02% YoY), and the FY2012 full-year result was -$4.5 million, down 29.02% from the prior year.
• Equity Income for Q4 2012 stood at -$881000.0, up from -$1.6 million in the prior quarter.
• The five-year high for Equity Income was -$467000.0 in Q3 2011, with the low at -$3.9 million in Q2 2010.
• Historically, Equity Income has averaged -$1.3 million across 4 years, with a median of -$1.1 million in 2011.
• Annual changes were most pronounced in 2010 — Equity Income slumped 380.27% — and 2011, when it jumped 74.18%.
• Alnylam Pharmaceuticals' Equity Income stood at -$1.5 million in 2009, then jumped by 38.44% to -$916000.0 in 2010, then retreated by 4.15% to -$954000.0 in 2011, then climbed by 7.65% to -$881000.0 in 2012.
• The last three Equity Income figures came in at -$881000.0 (Q4 2012), -$1.6 million (Q3 2012), and -$1.1 million (Q2 2012), per Business Quant data.